265 related articles for article (PubMed ID: 16269995)
21. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.
Sarich TC; Wolzt M; Eriksson UG; Mattsson C; Schmidt A; Elg S; Andersson M; Wollbratt M; Fager G; Gustafsson D
J Am Coll Cardiol; 2003 Feb; 41(4):557-64. PubMed ID: 12598065
[TBL] [Abstract][Full Text] [Related]
22. Orally active direct thrombin inhibitors.
Weitz J
Semin Vasc Med; 2003 May; 3(2):131-8. PubMed ID: 15199476
[TBL] [Abstract][Full Text] [Related]
23. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
Boström SL; Hansson GF; Sarich TC; Wolzt M
Thromb Res; 2004; 113(1):85-91. PubMed ID: 15081569
[TBL] [Abstract][Full Text] [Related]
24. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Mouret P; Rosencher N; Eskilson C; Nylander I; Frison L; Ogren M;
Thromb Haemost; 2003 Feb; 89(2):288-96. PubMed ID: 12574809
[TBL] [Abstract][Full Text] [Related]
25. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
Andersen JC
Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
[TBL] [Abstract][Full Text] [Related]
26. [Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome].
Slavina NN; Averkov OV; Gratsianskiĭ NA
Kardiologiia; 2005; 45(12):11-6. PubMed ID: 16353041
[TBL] [Abstract][Full Text] [Related]
27. Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
J Thromb Haemost; 2007 Jun; 5(6):1237-42. PubMed ID: 17362226
[TBL] [Abstract][Full Text] [Related]
28. Effect of different anticoagulants on multiple electrode platelet aggregometry after clopidogrel and aspirin administration in patients undergoing coronary stent implantation: a comparison between citrate and hirudin.
Zhang HZ; Yu LH; Kim MH
Platelets; 2013; 24(5):339-47. PubMed ID: 22774770
[TBL] [Abstract][Full Text] [Related]
29. [Antithrombotic treatment protocols in interventional cardiology].
Barragan P; Teuma X; Botosezzy I; Bouvier JL; Comet B; Commeau P; Macaluso G; Roquebert PO
Arch Mal Coeur Vaiss; 2001 Nov; 94(11 Suppl):1267-73. PubMed ID: 11794968
[TBL] [Abstract][Full Text] [Related]
30. Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
Wong PC; Crain EJ; Watson CA; Wexler RR; Lam PY; Quan ML; Knabb RM
J Thromb Thrombolysis; 2007 Aug; 24(1):43-51. PubMed ID: 17323133
[TBL] [Abstract][Full Text] [Related]
31. Low molecular weight heparins in the cardiac catheterization laboratory.
Montalescot G; Cohen M
J Thromb Thrombolysis; 1999 Jun; 7(3):319-23. PubMed ID: 10373715
[No Abstract] [Full Text] [Related]
32. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Elg M; Gustafsson D; Deinum J
Thromb Haemost; 1997 Oct; 78(4):1286-92. PubMed ID: 9364999
[TBL] [Abstract][Full Text] [Related]
33. Ximelagatran: a new oral anticoagulant.
Hrebickova L; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(6):397-408. PubMed ID: 14633322
[TBL] [Abstract][Full Text] [Related]
34. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
Karnicki K; Leadley RJ; Baxi S; Peterson T; Wysokinski W; McBane RD
Thromb Haemost; 2008 Apr; 99(4):759-66. PubMed ID: 18392334
[TBL] [Abstract][Full Text] [Related]
35. Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Danchin N; Aïssaoui N
Cardiovasc Drugs Ther; 2010 Aug; 24(4):325-30. PubMed ID: 20714797
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of deep vein thrombosis. Current and future questions].
Fiessinger JN
Bull Acad Natl Med; 2001; 185(8):1463-71; discussion 1471-3. PubMed ID: 11974967
[TBL] [Abstract][Full Text] [Related]
37. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice.
Lee H; Sturgeon SA; Mountford JK; Jackson SP; Hamilton JR
Br J Pharmacol; 2012 Aug; 166(7):2188-97. PubMed ID: 22428607
[TBL] [Abstract][Full Text] [Related]
39. [Prophylaxis and treatment of venous thromboembolism: the role of new antithrombotic drugs].
Falciani M; Imberti D; Prisco D
Recenti Prog Med; 2005 Apr; 96(4):196-204. PubMed ID: 15932039
[TBL] [Abstract][Full Text] [Related]
40. Optimal antithrombotic treatment for percutaneous coronary intervention.
Kadakia RA; Ferguson JJ
Minerva Cardioangiol; 2005 Feb; 53(1):15-42. PubMed ID: 15788977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
